US 12,239,572 B2
Wound treatment device
Ross I. Donaldson, Lawndale, CA (US); Oliver Buchanan, Lawndale, CA (US); Muhammed Hamdan, Lawndale, CA (US); Jonathan Armstrong, Lawndale, CA (US); John Cambridge, Lawndale, CA (US); and Nely Cristerna, Lawndale, CA (US)
Assigned to Critical Innovations, LLC, Lawndale, CA (US)
Filed by Critical Innovations, LLC, Lawndale, CA (US)
Filed on Jul. 28, 2022, as Appl. No. 17/876,187.
Claims priority of provisional application 63/227,251, filed on Jul. 29, 2021.
Prior Publication US 2023/0030893 A1, Feb. 2, 2023
Int. Cl. A61F 9/00 (2006.01); A61M 35/00 (2006.01)
CPC A61F 9/0008 (2013.01) [A61M 35/10 (2019.05)] 19 Claims
OG exemplary drawing
 
1. An ocular and/or periocular wound treatment device, comprising:
a deployment system initially containing a therapeutic agent and including tubing configured to connect the deployment system to an eye shield assembly;
an eye shield assembly, the eye shield assembly including:
a means for attachment to a patient with a temporary adhesive
at least one raised connector extending upwardly from the eye shield assembly configured to connect to the tubing, the raised connector defining an aperture through the eye shield assembly through which the therapeutic agent is configured to be delivered through the eye shield assembly, and
one or more passages to allow gas to escape, the one or more passages being planar openings through the eye shield assembly at different locations than the aperture through which the therapeutic agent is configured to be delivered through the eye shield; and
wherein the device may continuously remain in place during and after therapeutic agent delivery with the one or more passages allowing gas to escape from the eye shield assembly to prevent buildup of pressure in the eye shield from damaging the patient's eye,
wherein the therapeutic agent comprises a thermoreversible polymer formulation including a poloxamer.